Glenmark To Spend $100 Million On U.S. Production Plant By 2019
This article was originally published in PharmAsia News
Executive Summary
Glenmark Pharmaceuticals has decided to follow the field and establish a production plant in the U.S. to escape the reputation of India-based plants failing to meet international standards in terms of quality.